SEATTLE, Dec. 4 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. today announced that certain data regarding the Company's TRU-016 program will be presented at the 48th annual meeting of the American Society of Hematology (ASH). The meeting will be held December 9-12, 2006, at the Orange County Convention Center in Orlando, Florida.
The poster and oral session details are as follows: Sunday, December 10, 2006, 9 a.m. ET Poster Session: [2097.5] CD37-SMIP(TM) Drug Induced Caspase Independent Cellular Cytotoxicity Is Associated with Activation of Phosphotyrosine- Mediated Signaling Events in Primary Chronic Lymphocytic Leukemia (CLL) B Cells. Session Type: Poster Session, Board #275.5-II Sunday, December 10, 2006, 5 p.m. ET Oral Session: [135] NK Cells Contribute Significantly to the Innate Immune Effector Role of CD37-Specific SMIP in CLL and NHL. Session Type: Oral Session About Trubion
Trubion is a biopharmaceutical company creating a pipeline of product candidates to treat autoimmune disease and cancer. The Company's product candidates are novel proteins known as single-chain polypeptides and are designed using its SMIP(TM) custom drug assembly technology. In less than 24 months, the Company designed, developed and submitted to the FDA an Investigational New Drug application for its lead product candidate, TRU-015, which is currently being tested in a Phase IIb clinical trial for the treatment of rheumatoid arthritis. In December 2005, the Company entered into a collaboration agreement with Wyeth for the development and worldwide commercialization of certain therapeutics, including TRU-015. In addition, Trubion's TRU-016 program targets CD37, an antigen present on B cells, for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Subject to satisfactory completion of preclinical testing of TRU-016, the Company expects to file an IND for TRU-016 in the second half of 2007. Trubion currently retains all development and commercialization rights for the TRU-016 program. For additional information visit www.trubion.com.
Forward Looking Statements
Certain statements in this release may constitute "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934 and Section 27A of the Securities Act of 1933. These statements include, but are not limited to, those related to the company's future clinical development programs and the timing thereof, future clinical development plans, the details of the clinical trials and the timing of regulatory applications and action. These statements are based on current expectations and assumptions regarding future events and business performance and involve certain risks and uncertainties that could cause actual results to differ materially. These risks include, but are not limited to, risks associated with the ability of the company to successfully conduct clinical trials for TRU-015 and other SMIP candidates, the uncertainty of the FDA approval process and other regulatory requirements, the therapeutic and commercial value of Trubion's drug candidates, the company's collaboration relationship with Wyeth, including its ability to receive milestone payments from Wyeth, and risks associated with defending and enforcing any patent claims and other intellectual property rights; and such other risks as identified in the company's quarterly report on Form 10-Q for the period ended September 30, 2006 and from time to time in other reports filed by Trubion with the U.S. Securities Exchange Commission. These reports are available on the Investors page of the company's corporate Web site at www.trubion.com. Trubion undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.
TRBN-G Contact: Jim DeNike Investor Relations Trubion Pharmaceuticals, Inc. (206) 838-0500
Trubion Pharmaceuticals, Inc.CONTACT: Jim DeNike, Investor Relations of Trubion Pharmaceuticals, Inc.,+1-206-838-0500
Web site: http://www.trubion.com/
